BMJ:早起不赖床有助于降低乳腺癌风险

2019-06-28 MedSci MedSci原创

研究认为,早起人群的乳腺癌风险较低,过长的睡眠时间可能导致乳腺癌风险增加

近日研究人员检查了睡眠特征对乳腺癌风险的影响。

2个队列女性参与研究,UK Biobank队列包含156848名妇女,7784例乳腺癌诊断,BCAC队列包含122 977例乳腺癌病例和105 974名对照者。考察参与者自我报告的入眠时间类型(早晨或晚上)、失眠症状和多变量回归中的睡眠持续时间,以及与这些睡眠特征相关的遗传变体。

UK Biobank队列中,早起偏好与乳腺癌呈负相关(HR=0.95),而睡眠时间和失眠症状与乳腺癌风险无关。通过对341个与入眠时间相关的单核苷酸多态性(SNPS)、91个与睡眠时间相关的SNPS和57个与失眠症状相关的SNPS分析可解释早起偏好对乳腺癌的保护作用。BCAC研究支持早起偏好(OR=0.88)和睡眠时间延长(每增加1小时OR=1.19)对乳腺癌风险的影响。

研究认为,早起人群的乳腺癌风险较低,过长的睡眠时间可能导致乳腺癌风险增加。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1770319, encodeId=5c861e7031962, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Sep 11 02:11:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818628, encodeId=df3c1818628f6, content=<a href='/topic/show?id=dff998116f9' target=_blank style='color:#2F92EE;'>#降低乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98116, encryptionId=dff998116f9, topicName=降低乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=fengyqf, createdTime=Mon Feb 24 12:11:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848776, encodeId=479d1848e7641, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Sep 09 00:11:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061855, encodeId=c3022061855eb, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Apr 14 14:11:00 CST 2020, time=2020-04-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1770319, encodeId=5c861e7031962, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Sep 11 02:11:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818628, encodeId=df3c1818628f6, content=<a href='/topic/show?id=dff998116f9' target=_blank style='color:#2F92EE;'>#降低乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98116, encryptionId=dff998116f9, topicName=降低乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=fengyqf, createdTime=Mon Feb 24 12:11:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848776, encodeId=479d1848e7641, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Sep 09 00:11:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061855, encodeId=c3022061855eb, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Apr 14 14:11:00 CST 2020, time=2020-04-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1770319, encodeId=5c861e7031962, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Sep 11 02:11:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818628, encodeId=df3c1818628f6, content=<a href='/topic/show?id=dff998116f9' target=_blank style='color:#2F92EE;'>#降低乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98116, encryptionId=dff998116f9, topicName=降低乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=fengyqf, createdTime=Mon Feb 24 12:11:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848776, encodeId=479d1848e7641, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Sep 09 00:11:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061855, encodeId=c3022061855eb, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Apr 14 14:11:00 CST 2020, time=2020-04-14, status=1, ipAttribution=)]
    2019-09-09 gaoxiaoe
  4. [GetPortalCommentsPageByObjectIdResponse(id=1770319, encodeId=5c861e7031962, content=<a href='/topic/show?id=df9c23e868a' target=_blank style='color:#2F92EE;'>#乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23786, encryptionId=df9c23e868a, topicName=乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9538161180, createdName=gaoxiaoe, createdTime=Wed Sep 11 02:11:00 CST 2019, time=2019-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818628, encodeId=df3c1818628f6, content=<a href='/topic/show?id=dff998116f9' target=_blank style='color:#2F92EE;'>#降低乳腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98116, encryptionId=dff998116f9, topicName=降低乳腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=fengyqf, createdTime=Mon Feb 24 12:11:00 CST 2020, time=2020-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848776, encodeId=479d1848e7641, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Sep 09 00:11:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061855, encodeId=c3022061855eb, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Apr 14 14:11:00 CST 2020, time=2020-04-14, status=1, ipAttribution=)]
    2020-04-14 sjq027

相关资讯

JACC:ACEI和β受体阻滞剂能减少化疗乳腺癌患者的心脏毒性

曲妥单抗对表皮生长因子受体2(HER2)阳性的乳腺癌非常有效,但其会损伤左室收缩功能。本研究的目的旨在评估ACEI或β受体阻滞剂能否减少曲妥单抗引起的心脏毒性。本次随机双盲对照研究纳入了468名HER2阳性乳腺癌女性,平均年龄 51±10.7岁,随机分成了赖诺普利组、卡维地洛组和安慰剂组。经过2年时间的随访,安慰剂组患者的心脏毒性发生率为32%,卡维地洛组为29%,赖诺普利组为30%。在接受蒽环类

Arvinas靶向雌激素受体的蛋白质降解剂ARV-471治疗乳腺癌,其IND申请获FDA授权

Arvinas宣布其靶向雌激素受体(ER)的蛋白质降解剂ARV-471治疗局部晚期或转移性ER阳性/ HER2阴性乳腺癌的新药研究申请(IND),已经获得美国食品和药物管理局(FDA)的授权。Arvinas预计将在2019年第三季度开始ARV-471的1期临床试验。

CA-CANCER J CLIN: 多种癌症的筛查指南

乳腺癌:40-54岁,1次/年,钼靶X线检查;55岁及以上,预期寿命长于10年,每年筛查2次。宫颈癌:21-29岁,1次/3年,常规的或巴式细胞法;30-65岁,1次/3年,巴式细胞法,或1次/5年,HPV检测+巴式细胞法;65岁以上,若在过去10年内连续3次巴式细胞法检测阴性或连续2次巴式细胞法+HPV检测阴性,则可终止宫颈癌筛查。PS. 宫颈癌疫苗注射与否,不影响筛查方案。子宫内膜癌:更年期的

欧盟批准辉瑞的PARP抑制剂Talzenna,用于治疗BRCA突变的乳腺癌

欧盟委员会宣布批准辉瑞的PARP抑制剂Talzenna(他拉唑帕利),用于治疗具有BRCA基因突变的局部晚期或转移性乳腺癌(MBC)患者。

患者如何评价乳腺癌手术质量?

乳腺癌是女性最常见的浸润性癌症,也是仅次于肺癌的女性癌症死亡的第二大凶手。目前,手术治疗仍是乳腺癌的主要治疗手段,并在很大程度上决定了乳腺癌患者的治疗效果以及生活质量。那么,作为患者,我们能否通过简单地方式来粗略地判断手术做得好不好呢?下面就来和大家分享一些评价乳腺癌手术质量的小技巧。